BMSN Archives - Page 3 of 6 - Blue Horseshoe Stocks

BMSN, ENTB, BIOF, PEIX & Extended Watchlist

Bio-Matrix Scientific Group, Inc. BMSN

We continue our coverage of BMSN this Tuesday morning following six consecutive sessions of positive moves for the stock. Last Monday, we focused on BMSN, having already seen upwards of 2400% in gains from the stock to that point. From Monday’s low of .0075, to the high Friday at .015, we added another 100% rip to our resume’ of gains since we’ve been tracking BMSN.

Currently on the chart, we have a very favorable set-up. The 50DMA is approaching the 200DMA, setting up for a Golden Cross, which is something we always like to see.

While the chart is beginning to appear top-heavy, we have yet to observe any of the signs of the stock being overbought. We continue to see higher lows and higher highs being maintained. However it is at this point that we’ll exercise extreme caution, because as many other stocks in this position have taught us in the past, a wave of profit-taking could cause a sell-off at any time. At that point, we’d like to see a penny hold as support for BMSN to continue to hold our interest.

___

Entest BioMedical Inc. ENTB

We’ve been keeping ENTB in our extended watchlist consistently since January 15th. Shortly following that date we saw a low of .001. The stock has been gaining steadily since that time, and hit a high of .0077 on Friday. In exactly one month’s time, ENTB managed to increase 670% in value for us, and we couldn’t be more pleased.

It’s worthwhile to note that ENTB is under the same management as our previously mentioned winner, BMSN.

The chart is exhibiting similar pattern to BMSN as well, so we want to look out for the 50DMA to continue to curl up to the 200DMA toward a potential Golden Cross.

___

Side Note:

BIOF and PEIX, are our two ethanol plays that have continued to bring us solid gains. Friday’s session was no exception. PEIX traded in a range from .393-.469, a gain of 19%, while the range on BIOF was 5.678-6.84, a 20.5% jump.

___

Extended Watchlist:
PPHM, ODP, OMX,

Marijuana Stocks Blazing to New Highs in 2013

On Monday, we encouraged everyone to check out one of our recent marijuana stock reports, where we highlighted no less than ten plays in the up-and-coming sector. We feel like a broken record at this point, having pounded the table on these stocks for a very long time, but we won’t quit parroting ourselves until we’re sure everyone understands: If you ever asked yourself “what is the next ‘big thing’?”, this is it. Marijuana stocks are the next big thing, and we’ve done our absolute best to show everyone we believe just that. It has become clear to most lawmakers that the advantages to ending marijuana prohibition, particularly from a fiscal standpoint, far outweigh any alleged drawbacks. The Marijuana Stock Index has risen over 900%% since October, and it’s no coincidence. Just take a look at this article explaining how the marijuana industry is gearing up for a “legislative windfall” regarding the legal status of the now mostly-illicit substance.

This week, MWIP has thus far traded in a range from .0585-.12 gaining 105% If you take into the account the low since we first mentioned MWIP (.0024), our total cumulative gains have reached a staggering 4900% as of yesterday’s high.

ERBB hit a high of .0163 yesterday, which represents move of 104% from this week’s previous low of .008.

___

PureSafe Water Systems, Inc. PSWS

PSWS has been a successful new play on our watchlist, performing very well so far this week. It first appeared on our extended watchlist on Monday, when it was trading as low as .0049. Yesterday the stock closed at the high of day at .0075, a 53% gain from Monday’s low.

This morning’s PR:

PureSafe Water Systems, Inc. (OTCQB: PSWS) Announces The Signing Of An Exclusive Worldwide Sales And Marketing Agreement And An Engineering Package Agreement
PLAINVIEW, N.Y., Feb. 13, 2013 /PRNewswire via COMTEX/ — Leslie Kessler, CEO of PureSafe Water Systems, Inc. (OTCBB: PSWS) (OTCQB: PSWS), is pleased to announce the signing of strategic agreements with Global Equipment Marketing, Inc. (“GEM”) and Engineering Technologies Group, Inc. (“ETG”) of Hopkinton, MA.
___

Peregrine Pharmaceuticals, Inc. PPHM

Those of you who have followed us for long enough, know that PPHM is an old-time favorite of ours. We’ve tracked this play for the better part of a year now, and in that span, we’ve seen it make some stellar gains.

PPHM first began appearing in our watchlist in mid-August 2012, as it ran from 2.30-3.09, after which time it pulled back to 1.76, before skyrocketing as high as 5.50.

More recently, we’ve been looking for PPHM to challenge 2.78, a recent swing high, that represents the current main area of resistance on the chart. The company released favorable test results for its pancreatic cancer treatment this morning, so be sure to check this stock out if you have not already done so.

This morning’s PPHM headline reads:

Peregrine Pharmaceuticals Announces Results From Phase II Clinical Trial of Bavituximab in Stage IV Pancreatic Cancer
Top-Line Results Demonstrate Signs of Anti-Tumor Activity; a 28% tumor response rate as opposed to the control group which posted a rate of just 13% These statistically significant results have the stock trading up 20% pre-market, so today should get interesting for PPHM.___

Extended Watchlist:
ADCF, BMSN, GRPN, ZNGA, IGC,

MWIP, BMSN, LWSP & Extended Watchlist

The following stocks have collectively brought us over 5000% in gains in just four months. No, seriously. We’re not making this up, read ahead and see for yourselves:

MediSwipe, Inc. MWIP

MWIP went on to see its fourth straight day of gains on Friday, after appearing in our morning report. The stock ended up touching a high of six cents from a low of .0491, gaining 22% intraday. We’d like to see support materialize at .049 as we begin this new trading week. Below that, we’d need a previous resistance level, .0455, to hold as support in the event of a consolidation.

MWIP, and indeed all the other marijuana related plays on our watchlist, have done an amazing job for us recently. For those of you who have not followed our recent coverage on the topic, we encourage you to check out one of our recent cannabis stock reports, containing no less than ten of our interests in the field of medical and legal marijuana.

Since we first mentioned MWIP on the morning of October 16th, the stock has traded in an astounding range from a low of .0024 this fall, consistently climbing its way on up to Friday’s high at .06 for a mind-blowing 2400%

BARCHART.COM is still giving MWIP a “100% Buy” Rating

___

Bio-Matrix Scientific Group, Inc. BMSN

Speaking of unthinkably epic gains, if you can believe it, BMSN has also afforded us the chance at 2400% in profits! Since appearing on our watchlist on December 26th, the stock was as low as .0003, and ran to a high of .0075.

We are extremely proud of our timing in alerting BMSN on the 26th, as it came just one tick above the ultimate low (.0002) that preceded this huge uptrend. In order to sustain its upward trajectory, we’ll need to see support hold in the .005 area, as pointed out on the chart below. We also show the next key area of resistance at a previous swing high at .0148.

___

Legacy Wine & Spirits International Ltd. LWSP

LWSP began appearing on our watchlist on January 16th, after which time we observed a low of .006, before the stock pulled in 283% in gains running to .023.

On Friday following another appearance in our extended watchlist, LWSP touched a low of a penny before running to .0175, a 75% intraday move.

The next key resistance comes at .018 and .023.

___

Extended Watchlist:
EXPU, IDGC, PSWS, PEIX, BIOF, ZNGA, CLSN

BMSN, CERP, COIN & Extended Watchlist

Bio-Matrix Scientific Group, Inc. BMSN

BMSN is a really good example of why we suggest that our readers keep a working watchlist of all of the stocks we mention, as there are instances when one of our more dated interests crops up with a new development that sends the stock on a ride. Such was the case with BMSN yesterday, as the company released a PR iterating the initiation of clinical trials for the company’s anemia treatment, HemaXellerate. As a result, yesterday’s trading carried the stock as high as .0062.

A week ago today, we mentioned that we’d like to see support hold at .0035 and .0021 to remain bullish on BMSN, which it did, in fact, manage. From the low of .0032 since last Wednesday’s mention, we are up 94% – From the low following our first ever alert (.0003 on Dec. 26th), yesterday’s high represented an unbelievably impressive gain of 1967%

Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I(TM) Stem Cell Drug for Aplastic Anemia

Clinical Trial to Evaluate “First in Class” Approach to Bone Marrow Failure Diseases

SAN DIEGO, CA, Feb 05, 2013 (MARKETWIRE via COMTEX) — Regen BioPharma a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company’s HemaXellerate I(TM) stem cell drug in patients with drug-refractory aplastic anemia.
___

Cereplast, Inc. CERP

We first mentioned CERP as a feature on January 24th, at which time we saw a low of .023. On the 25th, it spiked 59% to .0365. This past Friday the stock saw another low of .0182, before running yesterday to a new high at .043, for an added gain of 136%, and bringing our total cumulative gains to 195% in just under two weeks’ time.

With the amount of momentum and volume we’ve seen trade through CERP recently, we definitely want to keep this one high on our watchlists.

Cereplast Provides Shareholder Update on Italian Application Decree & Announces $300,000 in New Revenue

EL SEGUNDO, Calif., Feb 05, 2013 (GLOBE NEWSWIRE via COMTEX) — Cereplast, Inc. (OTCQB:CERP) (the “Company”), a leading manufacturer of proprietary biobased, compostable and sustainable bioplastics, generated approximately $300,000 in new revenue during the last two weeks of January 2013. These orders received are in addition to the $500,000 of new revenue that was announced on January 23, 2013.

___

Converted Organics, Inc. COIN

COIN appeared on our extended watchlist yesterday, and thus posted a sizable gain, running from .0019-0029, only to close the day at .0025. That gave us a quick chance at up to 53% in intraday gains.
___

As most of you are undoubtedly aware, we first began really zeroing in on cannabis stocks back in October. From our continued reports on the subject this week, we have seen even more gains to add to the already monumental profits that these plays have afforded us. Our running tally of tracked pot stocks totaled 10 at the start of this week. We are all but certain that even more will crop up (no pun intended), as the fervor over this newly expanding market sector continues to intensify.
___

Extended Watchlist:
SFOR, SCXN, CCRY, JOEZ, CNAM, CLSN

BMSN, KERX & Extended Watchlist

Bio-Matrix Scientific Group, Inc. BMSN

BMSN has been a main point of focus for us this year. We first began paying close attention to BMSN towards the end of 2012 when it was trading as low as .0003. Yesterday, the stock had another rockstar performance, reaching new highs and cracking through another major resistance point at .0035 (200DMA).

After the initial surge we saw from .0003-.0024, we wanted to see support hold off of .001. Now that we have hit new highs, we are raising the bar and looking for new support to hold at .0035, or below that, the 20DMA of .0021. If we can see these areas hold as support, we are going to remain bullish on BMSN.

Over the span of our coverage on BMSN, we have been afforded the opportunity at an accumulation of up to 1400% in possible gains from .0003 to yesterday’s high of .0045

Most Recent News:

SAN DIEGO, CA, Jan 24, 2013 (MARKETWIRE via COMTEX) — Regen BioPharma, a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today publication in a peer reviewed medical journal the scientific basis for its HemaXellerate(TM) bone marrow failure product. The manuscript is available at http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf. The publication is an overview of the Investigational New Drug (IND) application that the company plans to file for initiating clinical trials.

Keryx Biopharmaceuticals, Inc. KERX

KERX earned us a spot in the Penny Stock Rumble on Tuesday, racking up another solid day of gains, and hitting a high of 8.79. That brings our total possible profits to a very respectable 154%

We are going to be monitoring the activity on KERX following yesterday’s announcement regarding the comnpany’s planned $55M public offering.

Yesterday’s News:

NEW YORK, Jan. 29, 2013 /PRNewswire via COMTEX/ — Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) today announced that it has commenced a $55 million underwritten public offering of shares of its common stock. In connection with this offering, Keryx expects to grant to the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. J.P. Morgan is acting as the sole book-running manager in the offering.

Extended Watchlist:
SCXN, ITNS, MYRY, SWVI, ONCI, ENTB